Sudhakar Akul Yakkanti is a Founder Director of Cell Signaling Tumor and Retinal Angiogenesis Laboratory, Boys Town National Research Hospital, Omaha, NE, USA. He is a Clinical Professor of Creighton University and Nebraska Medical Center. He did his postdoctoral training at Harvard Medical School Boston, USA (2003). He has received P.hD (2001), M.Phill (1997) and M.Sc (1995) degrees in life sciences from University of Hyderabad and B.Sc in Biology from SK University (1993) from India. He was received President’s fellowship, GATE and CSIR fellowships from government of India. He received Mahindra & Mahindra Travel Award and YCS Award from FAMRI. He received Bio-Bio Young Scientist Award from OMICS and RO1 grant award from NIH/NCI. He is serving as AIBS/NIH-Grant reviewer. He has published more than 40 research articles including Science, JCI, Cancer Cell, PNAS, Blood ect. He is serving as an Editor-In Chief, Editor, Associate editor and Editorial board member of 13 reputed journals and serving as reviewer of 26 scientific journals.

Extracellular matrix and Integrin Signaling, Biology and significance of type IV collagen derived angioinhibitors, Endogenous angioinhibitors role in Cancer and tumor microenvironment, Hypoxic tumorangiogenesis, Mechanism of endothelial apoptosis, Bioequivalence & Bioavailability of endogenous circulating angioinhibitors.

Harvey I. Pass is a Phi Beta Kappa graduate of the Johns Hopkins University and Duke Medical School. After completing his cardiothoracic training at the Medical University of South Carolina and a year as a cardiac surgery attending physician, he devoted his career to treating thoracic malignancies including lung cancer, pulmonary metastases, esophageal cancer, and mesothelioma. Dr. Pass completed a 3-year senior fellowship in the Thoracic Oncology Surgical Branch of the National Cancer Institute (NCI). There, he was mentored by Dr. Jack Roth and Dr. Steven Rosenberg in developing novel clinical trials from laboratory investigations. Dr. Pass was appointed Head of Thoracic Oncology for NCI in 1986, and held this position for ten years. From 1996 to 2005, Dr. Pass built the thoracic oncology program at Karmanos Cancer Institute of Wayne State University. In 2005, Dr. Pass was recruited to be the first Director of the NYU Division of Thoracic Surgery. His laboratory at Bellevue Hospital is the home of the NCI-funded Early Detection Research Network Biomarker Discovery Laboratory for Mesothelioma, and the Clinical CORE for the NCI’s recently funded Mesothelioma Pathogenesis Program Project. He has solidified NYU’s 3-year Thoracic Fellowship Training Program for individuals interested in general thoracic surgery. The program trains superb surgeons and thoracic scientists for the future. Dr. Pass serves as an Ad Hoc reviewer for publications including New England Journal of Medicine, JAMA, International Journal of Cancer and Journal of Clinical Oncology. He is a vigorous advocate for patients with lung cancer and mesothelioma, serving as a Lung Cancer Alliance Board member, and Chairman of the Scientific Advisory Board for the Mesothelioma Applied Research Foundation. He has been awarded Castle Connolly’s Americas Top Doctors award for the last five years

Thoracic Oncology, Molecular Genetics, Clinical Trials, Mesothelioma, Lung Cancer, Lung Cancer Screening, Esophageal Cancer and Pulmonary Metastases.

William E. Grizzle is a board certified anatomic and clinical pathologist. He has been Principal Investigator of the Southern Division of the Cooperative Human Tissue Network since 1987 and Director of the Tissue Resource Facility at the University of Alabama at Birmingham since 1983. He is internationally recognized as one of the leading authorities in human tissue resources and has published extensively in this area. He is on the Board of Directors and is a founding member of the International Society for Biological and Environmental Repositories. Dr. Grizzle is an internationally recognized researcher with expertise in oral neoplasia. He was Associate Director of the UAB Oral Cancer Research Center (1996-2002). He is Head of the Program for Translational Research in Neoplasia, Department of Pathology, UAB, and Principal Investigator of one of the 3 Validation Laboratories of the Early Detection Research Network.

The early detection of epithelial neoplasias and on biomarkers associated with prognosis.

Peter E. Barker is a Project Leader/Biologist at Biochemical Science Division, National Institute of Standards and Technology (NIST), holds degrees from Cornell (B. A. Biological Sciences) and the University of Texas Graduate School of Biomedical Sciences (M.S./Ph.D., cell and molecular biology, M. D. Anderson Cancer Center, Houston). Following postdoctoral work in biology and human genetics at Yale (New Haven), he served on faculty at UAB (Assistant Professor of Biochemistry and Medical Genetics). After sabbatical work in molecular cytogenetics at DKFZ, Heidelberg (German Cancer Research Center), he was Staff Scientist at Cold Spring Harbor Laboratory prior to moving to NIST in 1997, and initiated the NIST/EDRN-NCI Cancer Biomarkers Reference Laboratory as Principal Investigator in 2000. Work in his lab on qdot imaging was covered on CNN (2004) and designated best paper at the 25th Army Science Conference (2006). He was a member of the NCCLS guidance committee on FISH in medical genetics. Current work is funded by the National Cancer Institute Early Detection Research Network (EDRN), NIH and NIST. He serves on editorial boards of Disease Markers, Clinical Proteomics and Biomarker Insights and has served on biotechnology study sections at NIH, NCI and NSF as reviewer and chairman, and FDA panelist. He is co-chair of the AACR-FDA-NCI Cancer Biomarker Collaborative (CBC), and a member of caHUB/NCI Working Group (2009).

Cancer biomarker validation, high-throughput genetic screening technologies, cellular bioimaging with semiconductor nanocrystals, and mtDNA/NUMTs bioimaging. With NIST and NIH funding, he is currently developing a national standard for HER2 testing in breast cancer. His work includes 91 peer-reviewed publications, and 86 published abstracts in human genetics, biotechnology and cancer biomarker validation.

Mong-Hong Lee is currently a Professor in the Department of Molecular and Cellular Oncology of University of Texas MD Anderson Cancer Center and a faculty member at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS). In 1993, Dr. Lee received his Ph.D. degree in Molecular, Cellular, and Developmental Biology from the University of Pittsburgh, where he received the Stanton C. Crawford Award for teaching excellence. He then went on to complete a postdoctoral fellowship while serving as a research associate at Howard Hughes Medical Institute and Memorial Sloan-Kettering Cancer Center (1993-1997).  After completing his fellowship, Dr. Lee came to M. D. Anderson in 1997 as an Assistant Professor (tenure track). He was promoted to his current position of Professor (tenured) in 2010. During his time at M. D. Anderson, Dr. Lee has been the principal investigator or a co-principal investigator for nine funded research projects. He also has been a grant reviewer for several funding agencies. Dr. Lee has been honored for his research activities, led by the Susan G. Komen Breast Cancer Foundation Research Award (2001), Fleming and Davenport Research Award (2001), and William G. McGowan Foundation Research Award (1998). In addition to research, for more than a decade, Dr. Lee has been a key contributor to the education of trainees at M. D. Anderson and the GSBS in a variety of ways. For example, at the GSBS, he has been the course coordinator for the Molecular Genetics of Human Cancer seminar since 2006 and an instructor for the Cancer Cell Signaling course since 2000. Dr. Lee has had a wealth of direct interaction with trainees throughout his career. Specifically, he has directly supervised 40 graduate students, 12 clinical residents and fellows, 12 undergraduate and Allied Health students, 9 postdoctoral research fellows, and 1 medical student. Furthermore, he has chaired or served on 71 examining committees, 67 advisory committees, and 39 supervisory committees. UT M. D. Anderson Cancer Center and the UT GSBS at Houston have well recognized Dr. Lee’s educational efforts. In 2009, he received the John P. McGovern Outstanding Teaching Award, which is given annually to a faculty member at M. D. Anderson and/or the GSBS. Most recently, he has recently been named the February 2010 Faculty Educator of the Month at MD Anderson Cancer Center. Also, he received the M. D. Anderson Outstanding Educator Award in 2003. Currently, Dr. Lee is an ad hoc reviewer for 25 journals. He also has been a guest editor for the journal Breast Diseases. Over the course of his career, Dr. Lee has authored more than 50 articles published in peer-reviewed journals, 4 book chapters, and 3 invited articles.

Characterizing the roles of Cdk inhibitors (CKIs) in cancer formation, and exploiting signaling regulation in cancer therapy. Research projects focusing on: 1) roles of two CKI molecules that he cloned in tumorigenesis; 2) COP9 signalosome signaling regulation; 3) investigating the impact of hypoxia and PIm1 kinase in drug resistance; 4) employing Aurora B kinase inhibitor for cancer therapy; 5) p53-MDM2 signaling regulation and DNA damage; 6) Myc ubiquitination regulation; 7) Glycolysis and cancer metabolism.

Ajay Rana is a Professor in the Department of Molecular Pharmacology and Therapeutics. He completed his education at Indian Institute of Chemical Biology, Jadavpur University, Calcutta, India.

Role of MAP kinases and phosphatases in cell growth, migration, metastasis, and cell death and survival pathways.

Kenneth Maiese is Professor of Neurology and Neurophysiology of the University of Medicine & Dentistry of New Jersey. He has been serves as editor-in-cheif, associate editor and editorial board member of 40 reputed journals.

Cancer, metabolic disorders, Cerebrovasculature ischemia and related diseases, central nervous system degenerative diseases.

Lily Yang is the Chair of Surgery in Cancer Research, Dr. Lily Yang leads the basic science research efforts of the Division of Surgical Oncology and is one of the Departments most well-funded researchers. Specializing in the development of novel approaches for detection and treatment of cancer. Her current research involves novel approaches for cancer treatment and detection and developing multifunctional and tumor targeted nanoparticles for non-invasive tumor imaging.

1) Targeting the inhibitor of apoptosis family of proteins, such as survivin and XIAP, for cancer therapy; 2) Signal pathways and molecular mechanisms that confer aggressive behavior and drug resistance of breast cancer cells (e.g. breast cancer stem cells); 3) Molecular pathways promoting the progression of breast cancer from ductal carcinoma in situ to invasive breast cancer; 4)The development of multifunctional nanoparticles for cancer detection using targeted tumor optical and MR imaging, drug delivery, and monitoring therapeutic responses.

Sridhar Mani is  Professor of  Medicine, Oncology and Genetics Miriam Mandel Faculty Scholar in Cancer Research, Albert Einstein College of Medicine, New York, USA.

Orphan nuclear receptors (those that lack a well defined physiologic ligand) control nearly every major physiologic and biochemical process in eukaryotes - cell metabolism (e.g., cholesterol, energy, bile acids), xenobiotic detoxification, cell differentiation (e.g., gastrulation, retinal development), circadian rhythm, and cancer cell growth and apoptosis (e.g., NURR77).

Vincent Wilson is a Professor of Toxicology in the Department of Environmental Sciences, School of the Coast & Environment at Louisiana State University, Baton Rouge, Louisiana. He received his PhD in Pharmacology & Toxicology from Oregon State University in 1980 and proceeded to postdoctoral studies in molecular genetics under the direction of Dr. Peter A. Jones at the University of Southern California Comprehensive Cancer Center.  With a focus on chemical carcinogenesis, Vincent then spent five years at the National Cancer Institute, NIH, Bethesda, MD, in the Laboratory for Human Carcinogenesis, under the direction of Dr. Curt Harris.  The attraction of an offer to build, develop and run a laboratory for DNA diagnostics for clinical genetics and oncology services drew him out of NCI to The Children’s Hospital, Denver, CO, and the Department of Pathology, University of Colorado Health Sciences Center for six years before accepting a faculty position at the Louisiana State University in 1994.  He served as Chair, Interdepartmental Program in Toxicology at LSU for eleven years.

1) Mechanisms in mutagenesis and carcinogenesis; 2) Determination of the importance of changes in DNA 5-methyldeoxycytidine and chromatin modification patterns to the physiologic and perturbed processes of embryogenesis, differentiation, aging, carcinogenesis, and epigenetic instability; 3) Genetic processes involved in aging, mutagenesis and carcinogenesis; 4) Single base instability, hypermutable phenotypes and oncogenic mutation frequencies; 5) Genotoxic markers of diagnostic value for environmental and human biomonitoring; 6) Genetic markers of diagnostic and prognostic value.

Masato Yamamoto received his M.D. from Osaka University School of Medicine in 1988 and his Ph.D. from Osaka University, School of Medicine in 1997. In 1999 he conducted a postdoctoral fellowship at the University of Alabama in Birmingham. He remained at the University of Alabama and his most recent appointments there were Research Associate Professor in the Division of Human Gene Therapy, Department of Surgery, Medicine, and Pathology and member of the Comprehensive Cancer Center. He joined the faculty of the Department of Surgery at the Univerity of Minnesota in August 2006.

GI-cancer translational research, Gene therapy of cancer, Adenoviral vectors.

Hari K. Koul is a Professor and Director of Research, Division of Urology and Department of Surgery at the University Of Colorado School Of Medicine, Denver, Colorado, USA. He is founding program Director for Urosciences Program and a member of the University of Colorado Cancer Center. He is an internationally recognized researcher in Urology.

Pathophysiology of kidney stone disease, prostate cancer, bladder hypertrophy, urogenital development, and erectile dysfunction.The structure and function of MAP kinase signal transduction pathways in oxalate induced nephrotoxicity as well as the characterization of MAP kinase signal transduction pathways that are critical determinants in the patho-physiologies of bladder hypertrophy, benign prostatic hyperplasia and prostate cancer.

Vicente Notario graduated with a B.Sc. degree from the University of Salamanca, Spain, in 1974, and received his Ph.D. in Biology from the same institution in 1977. After completing post-doctoral training in the Department of Biochemistry of the University of Cambridge, England, and the U.S. National Cancer Institute, he joined the Department of Biochemistry at the Georgetown University Medical Center (G.U.M.C.) as a Research Assistant Professor, in 1986. Currently, Dr. Notario is Professor in the Departments of Radiation Medicine and of Biochemistry and Molecular & Cellular Biology. He is also Director of the Division of Radiation Research in the Department of Radiation Medicine. Dr. Notario has been Leader of the Radiation Biology & DNA Repair Program and the Molecular Targets & Therapeutic Resistance Program of the Lombardi Comprehensive Cancer Center, at the G.U.M.C. For over twenty years. His laboratory has focused on understanding molecular and cellular mechanisms of cancer initiation and progression as well as those involved in the acquisition of resistance to anti-cancer therapy, with emphasis on pathways that may be exploited to improve the treatment of metastatic cancers and to sensitize human tumors to chemotherapeutic drugs and radiation therapies. Dr. Notario has authored more than 135 publications. The quality and clinical significance of Dr. Notario’s contributions have been recognized and, consequently, continuously funded by the U.S. National Cancer Institute since 1986. Dr. Notario has also received international recognition in the form of numerous invitations to speak at specialized meetings and to become a member of the Editorial Boards of journals such as Cancer Research, The International Journal of Oncology, Current Cancer Therapy Reviews, The Open Cancer Journal, The Journal of Cell Death, The World Journal of Clinical Oncology, and others. Dr. Notario’s expertise in Experimental Molecular Carcinogenesis has been recognized also through invitations to participate in U.S. and international scientific review and advisory committees, such as those for the U.S. National Institutes of Health, the American Association for Cancer Research, the U.S. Department of Defense, the Israel Science Foundation, the Italian National Center for Rare Diseases, the Italian Association for Research on Cancer, and the Department of Education and Science of Spain. In addition, Dr. Notario has been invited to act as an ad hoc expert reviewer for over 50 specialized U.S. national and international scientific journals. His service to Georgetown University included terms in the G.U.M.C. Research Committee and various faculty search committees, the Medical School Admissions Committee and the Lombardi Comprehensive Cancer Center Executive Committee, and is currently serving as Chairman of the Georgetown Institutional Biosafety Committee.

Biochemistry, Molecular Biology, Radiation Biology, Molecular Carcinogenesis and Tumor Biology.

Deryl Troyer received his DVM in 1972 and a doctoral degree in anatomy, physiology and pathology in 1985 from Kansas State University. Dr. Troyer served as an assistant professor at the University of Illinois in Urbana, Illinois from 1985 to 1986, and was a visiting researcher in molecular genetics at Howard Hughes Medical Institute in Salt Lake City, Utah in 1988.  He has been a professor at Kansas State University since 1986.  He is co-discoverer of primitive stem cells within umbilical cord Wharton’s jelly, and a founding member of the Midwest Institute for Comparative Stem Cell Biology at KSU.  He is a recipient of the Otto Zietschman Prize in Experimental Embryology, and is a recipient of the Pfizer Award for Research Excellence as well as several teaching awards.

Investigating stem cells as a platform for specific delivery of anti-cancer molecules. Strategies employed to achieve this goal include utilizing genetically engineered cells for cancer gene therapy or utilizing the cells to deliver nanoparticles loaded with small molecule anticancer drugs.  In particular, utilizing these ‘stealth delivery cells’ for targeted magnetic hyperthermia (Stem cell biotechnology).

LuZhe Sun serves as Leader of Cell & Molecular Biology (CMB) Track of the Integrated Multidisciplinary Graduate Program (IMGP) and Associate Director for Translational Research at Cancer Treatment and Research Center. He participated in the discovery of the tumor suppressive activity of the transforming growth factor beta type II receptor in human colon carcinomas. His lab pioneered the use of a soluble TGFß type III receptor and a TGFß receptor kinase inhibitor for the inhibition of cancer growth, angiogenesis, and metastasis in various xenograft models of late stage human cancers. He lectures in Fundamentals of Biomedical Sciences course and serves as a module course director for the CMB Track core course - Advanced Cell and Molecular Biology. Dr. Sun has regularly been invited to serve on grant review panels for NIH and Department of Defense.My laboratory studies molecular mechanisms that regulate carcinogenesis and cancer cell growth, invasion, and metastasis using molecular and cellular biology techniques and animal model systems. One of the molecules we are currently studying is called transforming growth factor beta (TGFß). This growth factor has been shown to inhibit tumorigenesis and growth of some early-stage adenocarcinoma cells, yet stimulate cancer survival, stem cell phenotype, and metastasis in late-stage carcinoma cells. We are investigating molecular mechanisms that switch TGFß from tumor-suppressing to tumor-promoting and the role of TGFß signaling in tumor microenvironment in driving tumor progression. We are also developing therapeutic approaches involving TGF beta antagonists to block cancer metastasis.

Role of growth factors, steroid hormones, telomerase, and adhesion m cancer cells-Translational research using recombinant growth factor binding proteins, growth factor aerapeutics to inhibit tumor growth, angiogenesis and metastasis mal cells in tumor progression-Effect of ageing on mammary stem cell function and transformation.

Matteo A. Russo graduated in Medicine and Surgery (1969), Catholic University of Rome. Italy. Assistant Professor of General Pathology (1970),  University of Rome, Sapienza, Italy. Associate Professor of Experimental Oncology (1980), University of Rome, Sapienza. Full Professor of General Physiopathology (1986), University of Rome, Sapienza, Italy. Fulbright Scholar 1974-1976, University of Pennsylvania and Temple Univ, Phila., Pa., USA. Visiting Professor of Pathology, Thrombosis Center, Temple University, Phila (1977-1979). Adjunct Professor of Pathology and Pharmacology, (1980-1990). Temple University , Phila, Pa.USA. He has obtained many research grants, both in USA (US-Environmental Protection Agency # CR-808949 and WW Smith Charitable Trust) and Italy (MURST, CNR, AIRC, etc). Award for Experimental Oncology, Fondazione Assicurazioni Generali di Trieste (1982). Member of many scientific Societies (SIP, SIC, etc.) Member of the Superior Committee of Public Health.(2003-2005). Director of the Research Doctorate in Human Pathology of Univ of Rome, Sapienza. Malpighi award from the Malpighi and Holding International Altay Foundation (2005) Member of the National Committee for the Research of the Ministry of Health (2000-2009). Member of the Scientific Committee for the Excellence Centre of “Regione Lazio” (2006-). President of Biomedical Laboratory Technician School at Sapienza University of Rome. President of Ethical Committee of ASL of Frosinone, Italy (2004-2010) Member of Scientific Committee of IRCCS San Raffaele Pisana, Rome.

a) Mechanism of cell volume control independent from ATP-ase Na/K-dependent; b) Role of Ca2+ and cytoskeleton in the pathogenesis of necrosis and apoptosis; c) Cellular and molecular mechanisms of the consolidation of the white thrombus; d) Proinflammatory genes expression in tumor progression and in different human diseases; e) Mechanisms of molecular repair in post-mitotic cells: the role of endocrine, paracrin and mechano-coupled signaling and Sirtuins. He is the leader of three research groups of IRCCS San Raffaele Pisana, Rome, involved in building the molecular basis of mechano-coupled, electric-coupled and pharmaco-aided rehabilitation of skeletal muscle, myocardium, sensory receptors and neuronal paths.

Anil Wali  is a Program Director in the Diversity Training Branch for the Center to Reduce Cancer Health Disparities. He provides technical and scientific expertise and grants program administration guidance to trainees and early stage investigators. Dr. Wali joined CRCHD in 2009 from Wayne State University, Detroit Medical Center and NCI designated Comprehensive Cancer Center Barbara Ann Karmanos Cancer Institute where he served as Associate Professor in the Departments of Surgery and Pathology. Dr. Wali also served as Principal Investigator on a Veterans Administration Merit Review award funded project on the Role of Ubiquitin-Proteasome Pathway in Mesothelioma Carcinogenesis. Dr. Wali conducted NCI Clinical trial on asbestos exposed patient populations to determine their risk for developing Lung Cancer and Mesothelioma using high throughput Genomics and Proteomics technologies. Dr. Wali received his B.S. and M.S. degrees from the University of Kashmir, in Srinagar, India. He earned his Ph.D. at the Postgraduate Institute in Chandigarh, India. Dr. Wali completed postdoctoral training at the Institute for Environmental Medicine at the University of Pennsylvania at the FELS Institute for Cancer Research at Temple University, Philadelphia, PA and in the Department of Pathology at Thomas Jefferson University, Philadelphia, PA.

Lung Cancer, Genomics and Proteomics.

Richard J. Simpson is a Professor at University of Melbourne, Ludwig Institute for Cancer Research Parkville, Victoria, Australia.

Cancer Research.

Rajagopal Ramesh  is a Cancer Research Working Group Member of AACR Chemistry (2006-present). American Association of Cancer Research (AACR) Member (1997-present). ASCO Associate Member (2006-present) NPA - National Postdoctoral Association Associate Member (2006-present).

Novel gene-based therapeutics using viral and non-viral vectors with emphasis on translational cancer research. 1) Development and testing of non-viral and nanoparticle-based gene delivery for cancer treatment, 2) Antitumor and anti-angiogenic properties of IL-24. Their findings have lead to Phase I clinical trials for treatment of solid tumors.

Sanjay K. Srivastava is a Professor of Biomedical Sciences at Texas Tech University Health Sciences Center (TTUHSC), Amarillo, Texas, specializing in cancer biology and nutritional chemoprevention. Prior to his arrival at TTUHSC in 2007, Dr. Srivastava served as an Assistant Professor in the Department of Pharmacology, University of Pittsburgh School of Medicine and was a full member of the University of Pittsburgh Cancer Institute. He also served as Research Scientist at Mercy Cancer Institute, Mercy Hospital of Pittsburgh and did his post-doc from University of Texas Medical Branch at Galveston, Texas. Dr. Srivastava received a B.S. in Physics, Chemistry & Math and a M.S. in Biochemistry from Lucknow University, India. His Ph.D. is in Biochemistry and Toxicology from Industrial Toxicology Research Center, Lucknow and Kanpur University, Kanpur, India. His research interests include cancer biology, chemoprevention of cancers by naturally occurring nutritional agents, chemical carcinogenesis and cell signaling. Dr. Srivastava is currently funded by two R01 grants from the National Cancer Institute, NIH. He has authored more than 100 research papers and book chapters and is a member of the American Association for Cancer Research, Society of Toxicology and AAPS. Dr. Srivastava is in the editorial board of several journals and ad-hoc reviewer of numerous scientific journals including Cancer Research, Carcinogenesis, Neoplasia and Molecular Pharmacology and also member of the study section of the National Institute of Health (NIH), Department of Defense and Susan G. Komen Breast Cancer Foundation. Dr. Srivastava has been recipient of several awards including TTUHSC “President’s Excellence in Research Award”. His research work has been featured by news agencies including BBC, MSNBC, CBS, ABC, Science News etc. and can be obtained from the following: BBC News-Pancreatic Cancer..

The molecular mechanisms of chemotherapeutic agents of natural origin against pancreatic, ovarian, and breast cancers.The long term goals of Dr. Srivastava’s research program are to: •Identify novel dietary or synthetic chemopreventive agents •Understand their mechanism of action at the cellular and molecular level •Explore their efficacy in vivo in preclinical experiments with suitable animal models and to verify changes in surrogate biomarkers •Investigate the synergistic effects of dietary agents with chemotherapeutic agents against cancer cells •Use the information obtained in preclinical studies to design and conduct phase I clinical trials •Establish pharmacokinetic data for the anticancer agents in humans, which will help to optimize further phase II/III chemoprevention trials.

He is working as a Professor in the third affiliated hospital, Kunming Medical College, Kunming, China.

Signal transduction, Cell Cycle Biochemotherapy and  Molecular Carcinogenesis. Preclinical/clinical development of molecularly targeted cancer therapeutic agents and signaling networks, including molecular mechanism studies in vitro and in vivo of therapeutic agents and molecular carcinogenesis. Current research mainly focuses on investigation of the molecular and signaling transduction pathways.  Most agents are the regulators of signal transduction, cell cycle, apoptosis, angiogenesis, metastasis, differentiation, proteasome inhibition and DNA damage. Signal transduction including post translational modifications (acetylation, methylation, phosphorylation, cleavage) and molecular biologic events. The main signal transduction pathways he has studied are Ras/Raf/MEK/Erk, PKC/MAPK, PI3K/PKB/GSK3, NFk-B, PKA, proteasome, differentiation, cell cycle, caspase, cell death receptor, cell growth receptor, etc.

Sujit Basu completed M.D. in 1985 from University of Calcutta, India. He completed  Ph.D. in 1996 in Cancer Research from University of Calcutta, India. Currently, he is working as an Associate Professor of Pathology, Ohio State University (OSU), Columbus, OH, USA.

Translational Research, Tumor microenvironment including angiogenesis and vasculogenesis (including role of endothelial and hematopoietic progenitor cells) and the signaling pathways controlling this process. Neuroimmunology especially neuroimmune interactions in the periphery.

Jagat R Kanwar is an immunologist and molecular biochemist with an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He did his PhD from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Before joining Deakin University in 2006, he was a Senior Scientist/Senior Research Fellow in the University of Auckland, Auckland, New Zealand. During the past decade his research both academic and commercial has centered on understanding the pathophysiological mechanisms and/or finding treatments for a variety of chronic inflammatory diseases and different types of cancer. Dr Kanwar has published 55 research articles, 12 invited reviews and 5 book chapters, in highly ranked, international, peer-reviewed journals. These publications have added to the body of knowledge in the fields of immunology, cancer gene therapy, nanomedicine, cell biology and biotechnology, and have extended these disciplines. He is a key inventor on 9 international patents and has provided consultancy to 5 Biotechnology based companies. He is a member of editorial board for 7 international journals and a nominated member of more than 12 national and international societies including American Society of Nanomedicine. He has extensive and close collaborations with colleagues from New Zealand, Australia, Singapore, India, China and USA.

Nanotechnology based drug delivery of proteins/peptides, siRNA and miRNA to target cancer and chronic inflammation drug discovery for novel anticancer targets for cancer cell survival, death, arrest, and repair development of immunomodulatory and anti-inflammatory bioactives, proteins and peptides for neuroprotection development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of solid tumours (colon and breast cancers).

Sophia Ran is an Associate Professor in the Department of Medical Microbiology, Immunology and Cell Biology at SIU School of Medicine and a member of the SIU Simmons Cancer Institute (SCI). Dr. Ran is a member of the American Association of Cancer Research (AACR). She is a coordinator of monthly research seminars in SCI, serves on the organizing committee for the bi-annual SCI Research Symposium as well as on various committees of the School of Medicine.

Breast cancer, Head & Neck cancer, Tumor Physiology, Tumor Angiogenesis, Hematogenous Metastasis, Tumor Lymphangiogenesis, Lymphatic Metastasis, Inflammation and Cancer, Inflammatory Lymphangiogenesis, Tumor Models in vivo, Chemotherapy & Chemoresistance, Regulation of Transcription, VEGF and Angiopoietins, VEGFR-1, VEGFR-2, VEGFR-3, Tie-1 and Tie-2 Receptors.

Sekhar Konjeti is a Professor in Vanderbilt Department of Radiation Oncology
Medical Center North, USA.

Drug development assay, Screening Techniques.

Ratna K Vadlamudi received his doctorate in Molecular Biology from the University of Wyoming, Laramie, WY in 1994.  He completed his postdoctoral training at Harvard Medical School / Dana Farber Cancer Institute in 1997. His Academic appointments have included Assistant and Associate Professor in the Department of Molecular and Cellular Oncology, MD Anderson Cancer Center and Associate Professor, in the Department of Genetics, Stanley S. Cancer Center, LSUHSC New Orleans. Dr. Vadlamudi’s research has focused on understanding the molecular mechanism of Nuclear Receptor Signal transduction using Estrogen Receptor as a model system.

Characterizing the role of novel coactivators in estrogen mediated cell cycle progression, chromatin remodeling and non-nuclear signaling, developing transgenic and knock-out mouse models for coregulators; characterizing the role of coactivators in tumorigenesis / hormonal resistance; and identifying small inhibitors/peptides targeting ER coregulators for therapeutic intervention.

Chi-Yu Gregory Lee is a Professor in the Department of Obstetrics and Gynaecology, University of British Columbia, Columbia, Canada.

Research and Development of Antibody-Based Anti-Cancer Drugs. RP215 monoclonal antibody was shown to recognize specifically a carbohydrate-associated epitope located on the variable regions of cancer cell expressed immunoglobulins, designated in general as CA215.Structural elucidation of carbohydrate-associated epitope in CA215 which is recognized by RP215 monoclonal antibody (Mab). Humanizations of RP215 Mab for preclinical studies. Generations of Rat anti-idiotype Mabs as candidates for the development of anti-cancer vaccines in humans. Establishment of an Anti-GnRH receptor Mab, GHR106, as a substitute of short-acting GnRH analogs for antibody-based anti-cancer drugs, as well as preclinical studies. Elucidation of mechanisms of action for RP215 and GHR106 as antibody-based anti-cancer drugs. Elucidation of a carbohydrate-associated epitope recognized by RP215 monoclonal antibodies.

Kurt S. Zänker was started in 1967 at the Free University Berlin, Berlin by studying human and veterinary medicine. These studies were finished in the late 70´ at the University of Munich with doctorates (Ph.D. thesis) in both disciplines. During the postgraduate education, several terms for research were spent at Cambridge (England), Memorial Sloan-Kettering Cancer Center (New York) and the M.D. Anderson Hospital and Cancer Center (Houston).From 1973 to 1975, and was awarded for a Max-Planck-Fellowship for 3 years to continue the eduction in Biochemistry at the Max-Planck-Institute of Biochemistry, Martinsried/Munich.From 1976 to 1982 I was a senior scientist at the Institute of Experimental Surgery, Technical University Munich.From 1982 to 1986. He worked as a senior physician at the tumor out-patient´s department of the surgical clinic, Technical University Munich. In 1986, he was appointed as Professor for the Chair of Immunology and Oncology at the University Witten/Herdecke, which is the only private university in Germany. Most of the funding of the Institute is done by writing research proposals. The quality of the research has allowed him to continue this funding now for almost 24 years.

Basic and translational research concerning cell-cell communication/interaction, signal transduction and gene activation/silencing with special reference to lymphocyte tumor cell interactions and, from the molecular point of view, to the migration machinery of these cells as well as of fusion of premalignant tumor cells with soma/immunocompetent cells/stem cells.

Meena Upadhayaya  is Head of Department of Medical Genetics institute, School of Medicine, Cardiff University, UK.

The Genetics of Facioscapulohumeral Muscular Dystrophy, The Genetics of Neurofibromatosis.

Soares, Fernando Augusto is a Full Professor at University of São Paulo, São Paulo, Brazil and Head of the Department of Anatomic Pathology of the research and Medical Hospital A.C. Camargo, São Paulo, Brazil. He also serves as Head of MSc and PhD program. He received his M.D. degree from Faculty of Medicine at Santos in 1980, and completed a residency in Pathology at University of State of São Paulo, Botucatu, Brazil. After that he moved to the University of São Paulo at Ribeirão Preto as teaching assistant in Pathology from 1984 to 1989 when received his Ph.D. degree, becoming Assistant Professor of Pathology at the same University. He was Visiting Professor at McMaster University at Hamilton, ON, Canada from 1991 to 1993. In 1997 become Head of the Department of Anatomic Pathology at Hospital A.C. Camargo and in 2004 received the title of Full Professor.He is a senior investigator in several grants which have resulted in more than 200 per-reviewed scientific papers in international journals.  Dr. Soares is also associate Editor of the upcoming Journal of Hematopathology, former President of the Brazilian Society of Pathology, and President of the Latin American Society of Pathology

Dr. Soares’s main research expertise is in translational pathology with emphasis in biomarkers in diagnosis and prognosis of the tumors. His clinical expertise is in surgical pathology with emphasis in hematopathology.

Yu-Fei Jiao  is a Professor of the Department of Pathology, Hospital of Harbin Medical University, China.

Mechanisms of carcinogenesis and metastasis of the gastrointestinal cancer. Establishment of an enzymatic erythrocyte creatine assay to determine erythrocyte age and its clinical application. We established an enzymatic erythrocyte creatine assay, which is favorable for quantifying erythrocyte creatine, and has analytical characteristics suitable for routine work in clinical laboratories. Using this method, we investigated whether erythrocyte creatine can serve as a corrective index for HbA1c in patients with a shortened mean age of erythrocytes. Their study demonstrated that HbA1c decreased in inverse proportion to the increase in erythrocyte creatine because of a shortened mean age of erythrocytes, and that the abnormally decreased HbA1c value could be assessed with erythrocyte creatine. We also demonstrated that erythrocyte creatine can be used for predicting erythropoietic status and estimating hypersplenism in patients with liver cirrhosis.

Jing-Gung Chung is a Professor, Chairman, Department of Biological Science and Technology, China Medical University, Taichung, Taiwan (2002-2005) and Associate Professor, Department of Microbiology, School of Medicine, China Medical University, Taichung, Taiwan (1993-2002).

To Screen the Anticancer Activity of Compounds from Chinese Herbal Medicine and Natural Plants in Taiwan. Signal pathways of apoptosis which is induced by emodin in glima cancer cells. Regulation and function of drug resistance genes expression in cancer cells after exposed to examined agents.

P. Reddanna is the "Outstanding Scientist or Engineer in the State for the benefit of Industry, Trade or Agriculture (The Chelikani Atchuta Rao Memorial Cash Award of Rs. 7001/-) Instituted by Late Sri C.V. Sitaramaswamy, Past-President, FAPCCI" for the year 2006-07 has been awarded to Prof.P. Reddanna (Scientist), Professor and Founding Coordinator, Centre for Biotechnology, School of Life Sciences, University of Hyderabad, Hyderabad. The award will be presented by Dr.Y.S. Rajasekhara Reddy, Honorable Chief Minister of Andhra Pradesh on 4 December 2008. Dr P. Reddanna after getting his Masters (1976) and Doctorate (PhD) (1979) in Science, joined as lecturer at Sri Venkateswara University in 1982. In 1990 he moved to University of Hyderabad as reader and became professor in 1998. He did post doctoral research at Penn State University (1984-87) and was visiting faculty at Johns Hopkins University, USA (2005) and Humboldt University, Berlin, Germany (2004). Prof. Reddanna has been working in the area inflammation and cancer, specifically on the role of polyunsaturated fatty acids (PUFAs) and eicosanoids for the past 30 years. PUFAs such as arachidonic acid is mainly oxygenated by cyclooxygenase (COX) and lipoxygenase (LOX) pathways to generate eicosanoids such as prostaglandins, the mediators of inflammation & cancer and leukotrienes, the mediators of allergy and asthma. While working on basic research to understand the role of eicosanoids in reproduction, he also studied their role in inflammation and cancer, which helped him to interact with the leading pharma and biotech companies in the country. Some of the companies include Dr. Reddy′s Laboratories, Shantha Biotechnics, Indian Immunologicals, Surya Pharmaceuticals, Medgene Biotech, Laila Impex, Dabur Research Foundation, etc. Currently he has ongoing industrial research projects sponsored by Natco Pharma, Hyderabad; ABL Biotechnologies, Chennai, Celestial Laboratories, Hyderabad and Onconova Therapeutics, USA. The significant work done during the year of Award is in the area anti-cancer drug discovery programs in collaboration with the leading pharma industries. Prof. Reddanna, as Vice-President of All India Biotech Association (AIBA)- Southern Chapter and Secretary, India Chapter of Federation of Indian Biotech Associations (FABA), also played a key role in the organization of several seminars/conferences, including the recently concluded BioAsia 2008, a global biobusiness forum.In summary Prof. Reddanna, while trying to understand basic mechanisms involved in inflammation and cancer, has contributed immensely to the growth and development of Indian industry specifically in the area of drug discovery.

Eicosanoids, Inflammation and Cancer: Inflammation is a response to acute tissue damage caused by either injury or infection. Although inflammation is necessary response to injury or infection, chronic inflammation is clearly correlated with increased risk of developing cancer. Many of the processes involved in inflammation such as leukocyte migration, dilation of local vasculature with increased permeability and blood flow, angiogenesis are known to contribute to tumor growth, progression and metastasis. Eicosanoids, the oxygenated metabolites of arachidonic acid formed via the cyclooxygenase and lipoxygenase pathway, play a dominant role in inflammation. Among these prostaglandins, specifically prostaglandin E2 formed via COX-2 pathway are known to mediate inflammation. As a result the COX-2 inhibitors formed the new series of Non-Steroidal Anti Inflammatory Drugs (NSAIDs). In view of the established role of inflammation in cancer, a number of anti inflammatory drugs are being explored for cancer prophylaxis and treatment.

M.M.Misro is a Professor in Reproductive Biomedicine in the National Institute of Health and Family Welfare, New Delhi, India. He is a postgraduate in Zoology with specialization in Physiology and Biochemistry and completed his Ph.D in Male reproductive Physiology with special emphasis in Contraceptive Technology Development. He was Fellow of Rockefeller Foundation and did his post doctoral training in the Department of Pharmacology in the University of Iowa during 1984-1986. He is currently a member of the Editorial Board in the International Journal “Current Women’s Health Reviews and peer reviewer for many International Journals.

The processes of molecular regulation of germ cell apoptosis in the seminiferous epithelium.

Richard D. Finkelman is a Senior Director in Clinical Research AstraZeneca LP Clinical Pharmacology & DMPK Wilmington.

Cancer Research.

Prakash S. Bisen earned Ph.D. in  1972 and was awarded D.Sc in 1981 After his postdoctoral work, he joined as Assistant Professor at Jabalpur University and was elevated as Associate Professor. He then joined as Bhopal University as a  Professor of Microbiology in 1985.  Prof. Bisen was Visiting Professor at Institute of Environmental and Biological Sciences, University of  Lancaster, Lancaster, England  and Visiting Research Professor at the Department of Biological Sciences, The University of Illinois at Chicago, USA. He was U.S. National Science Foundation Fellow at University of California at Davis, USA in the Department of Bacteriology. Prof. Bisen was WHO/ UNESCO Fellow for One Year at Institute of Microbiology, Czechoslovak Academy of Sciences, Budejovika, Praha, Czechoslovakia; UNESCO/UNDP/ICRO and Hungarian Academy of Sciences Fellow at the Institute of Plant Physiology, Biological Research Center, Szeged, Hungary.  He is honoured with Life time Professorship of Bundelkhand University, Jhansi, UP, India. He is also Honorary Professor of Biotechnology at Jiwaji University and is currently pursuing his research in the field of Medical Biotechnology as Emeritus Scientist at Defence Research and Development Establishment, DRDO, Ministry of Defence, Govt. Of India, Gwalior 474002, India.

Medical Biotechnology.

Michael Eckart is a Director of Protein and Nucleic Acid facility at Stanford University, USA.

Protein/Peptide Chem Edman Sequencing, Peptide Synthesis, Physical Chemistry, SPR, Nucleic Acid Chemistry, DNA Sequencing DNA Synthesis, Gene Array, Genotyping, Real Time PCR, RNA Synthesis, Mass spectrometry MS-Nucleic Acids, MS-Proteins-Intact, Peptide Mass Mapping, Other Carbohydrate Analysis.

Danni Meany is Instructor of Pathology at the Johns Hopkins University School of Medicine and Director of General Chemistry Laboratories at the Johns Hopkins Hospital. She received her PhD in Chemistry from the University of Minnesota and clinical chemistry fellowship training from Department of Pathology, Johns Hopkins University.  She is American Board of Clinical Chemistry (ABCC) certified clinical chemist.

Cancer Biomarker Discovery, Cancer Biomarker Validation, Prostate Cancer, Proteomic Technologies, Assay Development, Clinical Chemistry.

Chulso Moon has a 1. Tenure Track Professorship in the Department of Oncology, Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine (2001-2007). 2. Principal Investigator, The Head and Neck Cancer Research Institute, The Johns Hopkins University School of Medicine (Director: Dr. David Sidransky) (2001-). 3. Attending physician, The Johns Hopkins Hospital (2001-2006). 4. Principal investigator, ONXY-015 cancer genetherapy program for advanced head/neck cancer (2001-2003). 5. Adjunct Professorship, Department of Otolaryngology and Head and Neck Surgery, The Johns Hopkins University school of Medicine (2008- Present). 6. Preceptor, Graduate Program in Human Genetics and Molecular Biology, The Johns Hopkins University school of Medicine (2005- Present, Thesis Advisor for Juna Lee, 2010 Ph.D. Candidate). 7. Director of Medical Oncology, Cleo Craig Memorial Cancer Clinic, The South-Western Medical Center, Lawton OK (2010-Present).

Cancer gene therapy.

Gary Guishan Xiao is a Director of the Functional Genomics and Proteomics laboratories at the Creighton University. Osteoporosis Research Center, is an internationally recognized expert in the field of proteomics and metabolomics of cancers and bone disease. Dr. Xiao earns his Ph.D. in molecular computational biology about a dozen years ago, focusing on structural modeling of ligand-enzyme interaction and prediction of protein refolding pathways during protein translational process. Dr. Xiao had his postdoctoral research trained in Baylor College of Medicine and UCLA, focusing on pharmacokinetics and biochemistry of non-steroid inflammatory drugs such as aspirin-derivatives and their target, human prostaglandin H synthases H1 and H2, and cell cycle regulation, especially, the role of c-Myc in cardiac termination differentiation. Dr. Xiao’s research at harbor UCLA medical Center and City of Hope National Cancer Center were highly focused on genomic and proteomic interpretations of diet-induced obesity/diabetes and its complications such cancers and osteoporosis. Dr. Xiao joined Osteoporosis Research Center at the Creighton University Medical Center since 2007. Dr. Xiao has been regular reviewer or ad hoc reviewer for several medial journals, different funding agency such as NIH and several journal Editorial Board members.

Functional genomics & proteomics analyses of complex disease Including osteoporosis and cancer (especially, breast cancer, pancreatic cancer and prostate cancer). Function of microRNA in estrogen signaling, functional proteomics (focusing on the role of protein posttranslational modifications in cancer and osteoporosis), and proteomics technology development.

Honglin Zhou is an Associate Director of Center for Resuscitation Science Translational Research Laboratory (TRL) at University of Pennsylvania Philadelphia.

Cancer science.

Demir Akin Congretionally Directed Medical Research Programs, Breast Cancer Research Program, National Cancer Institute, Alliance for Nanotechnology in Cancer,  Radiation Oncology Program, CDMRP/DoD,  American Association for Cancer Research (AACR), U.S. Civilian Research and Development Foundation (CRDF).

Biological Engineering and Micro/Nanomedicine, Genomics/Systems Biology, Gene Therapy/Microbiology/Virology.

Kailash C. Chadha is an Associate Member, Department of Molecular and Cellular Biology Roswell Park Cancer Institute Buffalo NY 14263 Associate Research Professor, Department of Cellular and Molecular Biology University of New York at Buffalo Roswell Park, Associate Professor of Oncology, Roswell Park Cancer Institute Buffalo, Research Professor Niagara University,  New York 14109 and Research Assistant Professor of Medicine, Department of Medicine School of Medicine State University of New York at Buffalo Buffalo NY 14214, USA.

During past 4 to 5 years, he has diverted most of my efforts in the area of prostate cancer research. (1) identification & development of new biomarkers for the early diagnosis and management of prostate cancer including androgen independent prostate cancer and (2) to determine the role of prostate-specific antigen (PSA) in regulating angiogenesis in prostate tumor growth & metastasis.

Ardeshir Hakam is an Associate Professor of Oncology, Pathology and cell biology. Currently, he is Director of Surgical Pathology at Moffitt Cancer Center and research institute and Program Director of Oncologic Surgical Pathology Fellowship at the University of South Florida. Dr. Hakam is a board certified Pathologist and Cytopathologist. His training includes Anatomic & Clinical Pathology Residency at University of Hawaii, school of Medicine and fellowship trainings in Genitor-urinary pathology at University of Pittsburgh Medical Center and Oncologic Pathology and Cytopathology at University of South Florida, College of Medicine. He has published many peer reviewed articles, and abstracts in national meetings.

Gynecological and urological malignancies.

Sun Jianguo is a Director of Oncology Institute, Xinqiao Hospital, Third Military Medical University, Chongqing, China.

MicroRNA in carcinogenesis and cancer stem cell-related microRNAs, lung cancer.

Paul Tchounwou is an Associate Dean of the College of Science, Engineering and Technology, Presidential Distinguished Professor & Director of the NIH RCMI-Center for Environmental Health and at Jackson State University, Jackson, Mississippi, USA. He earned his Sc.D. at Tulane University Medical Center (TUMC), New Orleans, Louisiana, USA. Currently, he is also Adjunct Professor at TUMC. He has published 134 peer-reviewed papers and book chapters, and made over 300 presentations at national and international conferences. He is currently Editor-In-Chief of International Journal of Environmental Research and Public Health (MDPI, Basel, Switzerland), and of Environmental Toxicology (John Wiley & Sons, New York, USA). He has taught toxicology, epidemiology, risk assessment and public health-related courses for more about 20 years. He is member of Delta Omega Honorary Public Health Society, American Association for the Advancement of Science, American Association for Cancer Research, American Public Health Association, National Environmental Health Association, Society of Toxicology, and New York Academy of Science. He is a reviewer of journals in the area of toxicology and health risk assessment. He has received several awards including the Millennium Award for Excellence in Research; National Role Model Award; AACR Faculty Scholar Award for Cancer Research and International Order of Merit.

Cellular and molecular mechanisms of metal-induced toxicity and carcinogenesis. Oxidative stress biomarkers associated with human exposure to toxic metals and pesticides. Apoptotic mechanisms and cell cycle modulation by chemotherapeutic drugs. Cytogenetic and mutagenic effects  associated with chemical exposure. Gene-environmental interactions in human diseases. Health risk assessment and management of hazardous substances.

Prakash Nagarkatti is currently an Associate Dean for Basic Science, Advisor to the Vice President for Research, and Carolina Distinguished Professor at the University of South Carolina School of Medicine. He received his Ph.D. degree from the Defense Research and Development Establishment and Jiwaji University in 1981 and pursued a post-doctoral fellowship at McMaster University. He is also the Director of NIH-funded Center of Research Excellence on Complementary and Alternative Medicine in Autoimmune and Inflammatory Diseases. He has held faculty positions at the University of Kentucky, Virginia Tech and Virginia Commonwealth University. He has received numerous awards from the International Congress of Mucosal Immunology, Society of Toxicology, and the Virginia Academy of Sciences. He has served as a Chair of several NIH Study Sections, Editorial Boards of journals and a reviewer for several national and international funding agencies. His research has generated more than $20 million and he has published over 140 papers.

Cancer Immunology and Immunotherapy, Complementary and Alternative Medicine, Inflammation, Autoimmune Diseases, Drug abuse research, Immunotoxicology, Environmental toxicology, Developmental Immunology, Cannabinoids.

Jimmy Thomas Efird is a Visiting Associate Professor of Center for Health of Vulnerable Populations  at University of North Carolina, USA.

Cancer science.

Eldad Zacksenhaus is an Associate Professor in the Department of Medicine, Department of Laboratory Medicine & Pathobiology and the Department of Medical Biophysics, University of Toronto.

Breast cancer and the tumor suppressor pRb pathway

Mitchell Ho is an Investigator and Head of the Antibody Therapy Unit in the Laboratory of Molecular Biology at the National Cancer Institute (NCI). Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign, where he studied monoclonal antibodies for the treatment of cocaine addiction as a National Research Service Award Fellow with Mariangela Segre. He completed postdoctoral studies with Ira Pastan at the NCI working on immunotoxin therapy of cancer. Research in Dr. Ho’s laboratory studies mesothelin, CA125/MUC16 and other cell adhesion molecules as therapeutic targets in order to develop novel antibodies and immunoconjugates to treat ovarian cancer, mesothelioma and liver cancer. He has developed the mammalian cell display method which is currently being used by investigators worldwide to identify and engineer therapeutic antibodies. Dr. Ho is a recipient of Mesothelioma Applied Research Foundation Award, and Ovarian Cancer Research Fund Individual Investigator Award.

Ovarian cancer, liver cancer.

Gloria I. Sanchez is an Associate professor in the School of Medicine at the University of Antioquia in Medellin, Colombia and leader of the research group Infection and Cancer. She earned her Ph.D. in Molecular Microbiology and Immunology from the Johns Hopkins Bloomberg School of Public Health in 2000 at which time she joined the University of Antioquia where she started a research program focusing on the area of Human Papillomavirus (HPV) and Cancer. From 2004-2006, she completed Postdoctoral Fellowships at the Catalan Institute of Oncology in Barcelona, Spain, at the Department of Internal Medicine and Human Genetics at University of Michigan, Ann Arbor Michigan. During postdoctoral training, she participated in a multicenter worldwide study defining the time trends of HPV infection in cervical cancer and defining the role of HPV on Head and Neck and other human cancers.

Since 2000 Dr. Gloria I. Sanchez has been conducting research on various aspects of HPV-induced carcinogenesis. High-Risk  Human Papillomavirus (HR-HPV) infection has been recognized as the necessary cause for cervical carcinoma. The lifetime incidence of cervical infection is estimated to be as high as 80% and almost 50% of women acquire HPV infection shortly after sexual debut but about 90% of these infections clear in around 1-2 years. Only infections that persist progress to dysplasia and cervical cancer. Current research is designed to understand how cofactors can influence the probability of HPV to become a persistent infection with particular attention to 1.Understand the contribution of HPV 16 variants and cell-mediated immune response mechanisms as risk factors for HPV persistence and cervical carcinogenesis. 2. To find new biomarkers of HPV persistence and cervical cancer. 3. To study the clinical application of new molecular biomarkers for risk stratification of HR-HPV positive women.

Qingrong Huang is an Associate Professor, Department of Food Science, Rutgers University at New Brunswick. 9/2008-8/2009 Cluster Coordinator, Nanotechnology Application to Foods Cluster, Center for Advanced Food Technology, Rutgers University 1/2008-present, Full member of Graduate Programs in Molecular Biosciences, UMDNJ/Rutgers University, and Department of Molecular Biology & Biochemistry-Rutgers 1/2003-present, Full member of Graduate Program in Bioresources Engineering-Rutgers University at New Brunswick. 9/2002-6/2008, Assistant Professor, Department of Food Science, Rutgers University at New Brunswick. 1/2000-8/2002, NIST ATP Postdoctoral Research Associate, Department of Chemical Engineering, Stanford University/IBM Almaden Research Center  Advisors: Drs. Curtis Frank and Robert Miller 2/1999-3/1999 Visiting Scientist, Intense Pulsed Neutron Source Division, Argonne National Laboratory. 6/1998-1/2000, Postdoctoral Research Associate, Department of Chemistry, Indiana-Purdue University, Advisor: Dr. Paul Dubin2 8/1993-5/1998, Research/Teaching Assistant, Department of Chemistry, University of Nebraska-Lincoln. 9/1989-7/1993, Research Assistant, Laboratory of Polymer Physics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences. 2010 American Chemical Society Young Scientist Award finalist. Distinguished Speaker, College of Agricultural, Consumer & Environmental Sciences, University of Illinois, November 19, 2009. Received 2007-2008. The Professor Endel Karmas Award for Excellence in Teaching Food Science, Department of Food Science, Rutgers University. Honorable Speaker for the Polymer Science Lecture Series, State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, May, 2007. Honorable Speaker for the Polymer Science Lecture Series, State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, May, 2006.

Food Nanotechnology and biopolymers, with specific research interest in: (1) structure and self-assembly of biopolymers; (2) development of nanoemulsion/nanoparticle-based, controllable, traceable, and targetable nutraceuticals/drug delivery systems; (3) nutraceutical/protein (including receptor proteins) interactions, protein/carbohydrate interactions; (4) chemical force microscopy/single molecular force spectroscopy; (5) small-angle neutron/x-ray scattering, dynamic light scattering, surface laser light scattering, rheology; and (6) DNA and antibody-based biosensors.

Dongfeng Wu is a Member: American Statistical Association (ASA)International Biometric Society-East North American Region (ENAR) Editorial Services Editorial board member, Journal of Biometrics and Biostatistics;Editorial board member, Journal of Modern Applied Statistical Methods.Ad-hoc Member/Reviewer a. National Institute of Health (NIH), Special Emphasis Panel ZRG1 PSE-C (58) and ZRG1 PSE-J (58) R, challenge grant proposals review, May 2009. b. Judge for Research!Louisville, 2008, 2009. c. Educational Testing Service (ETS) AP reader of Statistics, June 5-11, 2009. d. Chaired a session at the Joint Statistical Meeting (JSM)2006, Seattle, WA, and section title: “Spline-based methods.”Referee Statistics in Medicine; Information Sciences; Quality of Life Research; Cancer; Statistical Methodology; Printice Hall; W.H. Freeman and Company. Other Services: At University of Louisville, SPHIS Faculty Forum Committee member, School Academic Affair Committee member, School Curriculum Committee member; Department of Bioinformatics and Biostatistics Master’s Program Director. At Mississippi State University, University Academic Review Board, 2002-03, University of  Grievance Panel, 2005-2007, Departmental Statistics Committee, Departmental Computing and Technology Committee, Departmental Assessment Committee, Departmental Evaluation of Teaching Assistants Committee.

Cancer screening stochastic modeling, wavelet regression, Bayesian inference, smoothing spline, statistical decision theory, time series.

Porunelloor A. Mathew is an Associate Professor of Molecular Biology and Immunology, University of North Texas Health Science Center at Fort Worth, and Associate Director for basic research, Institute for Cancer Research, UNTHSC, Fort Worth, Texas. Dr. Mathew received his PhD in Biochemistry in 1987 from University of Pune, India. He did postdoctoral fellowships at University of Medicine and Dentistry of New Jersey and UT Southwestern Medical Center. He is a reviewer for several journals. Dr. Mathew was awarded a US patent for “Immuno activation of CS1 receptor in Natural Killer cells to inhibit tumor cell growth”. Dr. Mathew’s research has opened new NK cell based targeted immunotherapy for cancer.

Cancer immunology, Natural Killer cell receptors, Molecular basis of NK cell recognition and activation by tumor cells. Regulation of immune response by surface receptors, Role of NK receptors in autoimmune diseases (systemic lupus erythematosus) targeted immunotherapy for cancer.

Rajasekhar NVS Suragani has been working at Cell Biology Discovery Group, Acceleron Pharma, Cambridge, USA.

Cancer biology.

Rui Hai Liu has published more than 90 original scientific papers in peer-reviewed journals with average citations of 46.87 per paper. He has been ranked as one of the top 5 scientists by total citations, and ranked No. 4 by impact, average citations per paper (49.45), among the scientists in the field of Agricultural Sciences (including Nutrition and Food Science) by Institute of Scientific Information (ISI), in the January 1, 2000–February 28, 2010 time period. He has given more than 200 invited seminars and research presentations throughout the US and around the world. Dr. Liu was elected as a Fellow of the International Academy of Food Science and Technology (IAFoST) in 2008. He is also an elected Fellow of the Division of Agricultural and Food Chemistry (AGFD) of the American Chemical Society (ACS) in 2008, and elected Fellow of the Institute of Food Technologists (IFT) in 2010.

Diet and cancer, the effects of functional foods/nutraceuticals on chronic disease risks, and bioactive compounds in natural products and herbal remedies for anticancer and antiviral activity.  Specific interests include: 1) health benefits of antioxidants/phytochemicals in fruits, vegetables and whole grains; 2) food genomics and functional foods for disease prevention and health promotion targeted at cancers, aging, and inflammatory diseases; and 3) natural products and herbal formulations for antiviral activity to hepatitis B and C.

Zhou, B. Peter received extensive training in breast cancer research at the Department of Molecular and Cellular Oncology and Breast Cancer Research Program at the MD Anderson Cancer Center prior to the faculty appointment at UTMB and UK Markey.

Breast cancer metastasis, particularly the biology underlying the process of Epithelial-mesenchymal transition (EMT). In these EMT processes, epithelial cells acquire fibroblast-like properties and exhibit reduced intercellular adhesion and increased motility. Activation of this normally latent EMT program confers cancer cells a distinct advantage for invasion and metastasis to distant organs or tissues. Using biochemical and molecular approaches, my group is characterizing the functional roles of Snail and Twist, two major inducer of EMT, in breast cancer metastasis. Uncover altered signaling pathways that regulate metastasis in breast cancer and, by discovery these pathways, to identify molecules that may serve as the therapeutic targets for metastasis prevention

Sharad Singhal is a recipient of Junior Research Fellowship of council of Scientific and Industrial Research, 1985-1987.­ Recipient of Senior Research Fellowship of Council of Scientific and Industrial Research, 1987-1989.­ Postdoctoral Fellow, Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas, 1989-1992.­ Instructor, Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas, 1992-1997.­ Assistant Professor, Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas, 1997- Feb 1999. Arlington, Arlington, TX  March 1999- October 2004. Arlington, Arlington, TX  November 2004-November 2007.­ Associate Professor, Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Forth Worth, TX  December 2007-Present.

Multi-drug resistance in cancer, liposomal delivery, radiation poisoning, stress signaling and oxidative stress, carcinogenesis, syngeneic and xenografts model, role of RLIP76 in regulation of glycemic control.

Yanming Wang is an Associate P{rofessor of the Department of Radiology, Director of Radiopharmaceutical Division, Case Center for Imaging Research Case Western Reserve University Cleveland, USA.

Alzheimer’s association, cancer research.

Pratap Kumar is an Associate Professor of the Department of Urology, The University of Texas Health Science Center at San Antonio, TX, USA. As a member of the Editorial Board, he assists in establishing editorial policy for the journal and in evaluating the material which has been submitted by others in the field of cancer science for publication in the journal. This will entail several peer reviews a year and responsibilities to select other expert to review articles. Dr Kumar was chosen as member of the Editorial Board on the basis of his expertise in the field of molecular cancer prevention especially exploiting natural products in conjunction with standard of care with special reference to Genitourinary and gastrointestinal malignancies.

Molecular cancer, genitourinary and gastrointestinal malignancies.

Rajendra Sharma was a Research fellow, Rajasthan University, Jaipur, India (1975-1979). Synthesized 3,4:6,7-dibenzomorphans, the compounds related to 6,7- benzomorphans (potent analgesics). Evaluated pharmacological efficacy of substituted 3,4:6,7-dibenzomorphans Research Associate, All India Institute of Medical Sciences, New Delhi (1980-1981) Investigated the energetics of radiation induced DNA damage and its repair mechanisms in normal and cancer cells. Identified relationship between DNA repair and the rate of cellular energy supply. Post-doctoral fellow (1989-1991) Purified and characterized a novel membrane transport protein DNP-SG ATPase from human erythrocytes. Established involvement of DNP-SG ATPase in the transport of glutathione conjugates of electrophilic compounds in humantissues. Showed the expression of DNP-SG ATPase in different human tissues. Purified and characterized glutathione S-transferases from mammalian tissues. Suptdg. Chemist at KDMIPE, Dehradun, India ( April 1991- March 2000)Analyzed pollutants from the surrounding areas of oilfields of Indian sedimentary basins.Investigated the toxic impact of petroleum hydrocarbons on human tissues.Visiting Scientist at UTMB, Galveston, TX (April 2000-Sept. 2003) Stably transfected cultured cells (HLE B-3) with human glutathione S-transferase A4 gene and demonstrated role of 4-hydroxynonenal in cell cycle and apoptotic signaling.Purified and characterized recombinant human RLIP76 a non-ABC transport protein and demonstrated a major role of RLIP76 in the ATP-dependent transport of glutathione-conjugates and chemotherapeutic agents in human erythrocytes and cultured cells.Suptdg, Chemist at KDMIPE, Dehradun, India ( Oct 2003- Aug.2005): Team leader- Project entitled “DNA finger printing technique in oil exploration”.

1. To investigate the detoxification mechanisms of xeno- and endo-biotics by glutathione linked phase II enzymes particularly GSTs as well as their role in protection against oxidative stress.2. Role of 4-HNE in cellular signaling related to apoptosis, cell proliferation and transformation and modulation of its intracellular concentration by coordinated action of GSTs and RLIP76.3. Chemoprevention of Cancer by natural products: These studies are focused on the role of lipid peroxidation in the mechanisms of cancer prevention and cell killing by sulforaphane, curcumin and Withaferin A.

Carlos Telleria  is a Director, non-credit elective course on Medical Spanish. This course was created to respond to a necessity medical student manifested in that, in the course of their training, they encounter a growing number of Hispanic speaking patients. Chair, Medical Student Research Committee Organizer of the 2006 Medical Student Research Forum. Efforts were made to increase the visibility of the program. The bylaws of the program were modified. Main achievements were securing an expansion in number of scholarships funded, and, for the first time in the program, a research allowance to the hosting laboratories. Member of a task-force appointed by the Dean of Basic Biomedical Sciences to revise the core curriculum of the graduate program in Biomedical Sciences.Convener of the task force of a multidisciplinary research group on “Cell Growth Control.” The task force had the mission to perform an analysis of the strengths, weaknesses, opportunities and threats regarding this area of research in the Division of Basic Biomedical Sciences, with the final goal of helping direct research efforts and plans for the near future, Basic Biomedical Sciences Research Council Committee. This committee is formed by a group of faculty that advises the Dean of Biomedical Sciences on the research directions the Division should take.

Endocrine-related cancers and develop strategies for repurposing orrepositioning antiprogestin compounds originally developed as contraceptive agents to treat ovarian cancer in conjunction with standard chemotherapy.

Liang Xu is an Associate Professor of the Department of Molecular Biosciences at University of Kansas.

Molecular therapy targeting cancer and cancer stem cells, cancer biology, drug discovery and drug/gene delivery. Funded by multiple NIH and DOD grants, my lab is working on molecularly targeted cancer therapy and chemo/radiosensitization by modulating cell death signaling pathways, autophagy and apoptosis. We are exploring microRNAs as novel targets for cancer and cancer stem cells. Novel nanotechnology to develop nanovectors targeting cancer cells for siRNA/miRNA-based novel cancer therapeutics. Nanovectors targeting cancer stem cells and exploring novel molecular therapy for cancer stem cells.

Pavol Zubor is an Associate Professor of the Department of Obstetrics and Gynecology.

1. Gene expression profiling in histologically normal breast gland epithelium, breast cancer or breast fibroadenoma tissue from breast cancer/fibroadenoma patients. Research is focused on conditions between surrounding tissue and tumor profile in the linkage to the tumor origin using samples microdissected from preoperative core and definitive excisional biopsied tissue, as well. 2. Analysis of genetic loci (polymorphic sites or somatic changes/mutations) associated with breast or gynecological cancer risk and biological profile of the disease. 3. Development of sensitive methods for detecting of somatic mutations and epigenetic changes (e.g. methylation) in breast, endometrial and ovarian cancer tissues based on direct DNA sequencing, Taqman assay and high resolution melting analysis. 4. E6/E7 mRNA oncogenesis + other molecular markers expression analysis in women with premalignant and invasive cervical lesions. 5. FISH telomerase expression in cervical premalignant lesions and carcinomas.6. Determination of serum levels of circulating cell-free cancer DNA (cfDNA) and micro RNA.

Hong Zhang is an Associate Professor of the Department of  Biomedicine
University of Skövde, Sweden.

1) Pathological features of oesophagus cancer. 2) Mechanisms behind cell damage by free radicals and repair. 3) Mechanisms behind chemotherapy in human skin melanoma. 4) Molecular mechanisms behind chemotherapy and radiotherapy in colorectal cancers; Biomarkers for early diagnosis, better therapy and patients survival in colorectal cancer.

Yohei Maeshima is a Senior Assistant professor of Medicine, Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. He has received a PhD in Internal Medicine from Okayama University, Okayama, Japan in 1997. He has received a MD in Medicine from Okayama University, Okayama, Japan in 1991. He received 21 academic awards including the Young Investigator Award from the Japanese Society of Cardiovascular Endocrine and Metabolism in 2002 and the Young Investigator Award (Oshima Award) from the Japanese Society of Nephrology in 2005. He is serving as an academic committee member of Japanese Society of Nephrology and Japanese Society of Internal Medicine and an editorial board member of Fibrogenesis and Tissue Repair. He published more than 60 articles in international academic journals including Science, Cancer Cell, J Clin Invest, PNAS, Diabetes, J Am Soc Nephrol, Cancer Res, Kidney Int and JBC.

Vascular Biology, Nephrology, Pathology, Molecular Biology and Internal Medicine.

Jasvinder A. Singh is a rheumatologist-epidemiologist at the University of Alabama at Birmingham and a staff physician at the Birmingham Veterans Affairs Medical Center. 

Systematic reviews and meta-analyses of treatments for arthritis, outcomes research in patients with osteoarthritis, gout and joint replacement focused on patient-reported outcomes, quality of care assessment and development of treatment recommendations and quality indicators.

Suresh Koduru is a Research Scientist at Children’s Hospital Boston, Harvard Medical School, Boston. He has received a PhD in Biochemistry from University of Hyderabad, Hyderabad, India. He has completed his M.S. in Biochemistry from S.V.University, Tirupathi, Inida. He received “Paul Doubler” award for excellence in studying Primary Immunodeficiency” in Human/Animal models. He has published 13 papers in peer-reviewed journals and he is serving as a member for Sigma Xi at Harvard Chapter.

Tumor Immunology, Transgenic animals models for inflammation and T cell trafficking. Use of monoclonal antibody therapy for human diseases.

Nives Pecina-Slaus is an Associate professor at the department of biology and Head of the Laboratory of Neuro-oncology Croatian Institute for Brain Research Medical School, University of Zagreb. She has received her B.S. in 1990. her M.S. in 1992. from the University of Zagreb, Faculty of Math and Sciences, and her Ph. D. in the field of molecular oncology in 1998 from Medical School University of Zagreb. She was trained at Cold Spring Harbor Laboratory Undergraduate Research Program, New York, USA in 1990; Georgetown University, Washington DC, USA in 1991; at the Division of Molecular Medicine at the Ruder Boškovic Institute in Zagreb in 1993. She joined Croatian Institute for Brain Research team in 2003 and in 2004 was appointed Head of the Laboratory of Neurooncology Croatian Institute for Brain Research, Zagreb. In 2005 she was elected Senior Investigator (scientific rank of full professor) and in 2007 associate professor at the Department of Biology, School of Medicine. She teaches Medical biology and was mentor on numberous theses. She was granted and was/is leading as prinicpal investigator five scientific projects. Her resarch has led to publication of more than 100 publications - scientific papers, a book, abstracts and book chapters. Her main fields of reseach are cancer genetics, Wnt signaling pathway, brain tumorigenesis, tumor suppressor genes, oncogenes, genetic profiles of brain tumors. She acts as a reviewer for Ministry of Science, Education and Sports Croatia, for Slovenian Research Agency (ARRS) for National council for university education, many scientific peer-reviewed journals (Brain Research, The Journal of Pediatric Biochemistry; International Orthopaedics, European Spine Journal, Journal of Pediatric Neurology, Kidney International, PLOSOne; Genes and Cancer, Lijecnicki vjesnik, Croatian Medical Journal). She is a member on editorial boards of scientific journals Frontiers in Bioscience, Acta Clinica Croatica, Cancer Cell International and Scientific Advisory Board of Melanoma Molecular Project Map and member of the review board of Journal of Pediatric Biochemistry, Journal of Chinese Clinical Medicine, Journal of Pediatric Neurology. She was awarded two scientific awards by Croatian Medical Association and Academy of Medical Sciences for best paper in basic medical research for young scientist. She is a member of Croatian Society of Human Genetics, Croatian Medical Association, Croatian Biological Society, European Society for Human Genetics, European Association for Cancer Research, Croatian Society for Neuroscience.

Cancer genetics, Wnt signaling pathway, brain tumorigenesis, tumor suppressor genes, oncogenes, genetic profiles of brain tumors, beta-catenin, axin, E-cadherin, APC, loss of heterozygosity, microsatellite instability, protein expression.

Miguel Lopez-Lazaro is an Associate Professor in the Department of Pharmacology at the University of Seville, Spain. Graduated in Pharmacy, he received a PhD in the Department of Pharmacology and completed a Marie Curie Postdoctoral Fellowship in the Department of Cell and Molecular Biosciences at the Medical School of the University of Newcastle, UK. In 1999, he became Associate Professor of Pharmacology at the University of Seville, where he currently holds a tenured position. His current areas of interest/expertise include several aspects of cancer biology and pharmacology (anticancer agents from natural origin, topoisomerase-mediated DNA damage, cancer metabolism, and role of oxidative stress in carcinogenesis and cancer therapy).

Anticancer agents from natural origin, Topoisomerase-mediated DNA damage, Role of oxidative stress in carcinogenesis and cancer therapy, Cancer metabolism, Theories of carcinogenesis.

Thomas Wan is currently the Cytogeneticist in charge and Honorary Associate Professor of the Department of Pathology, Queen Mary Hospital, University of Hong Kong, Hong Kong. He is also the Visiting Professor of the Fujian Medical University and Honorary Professor of the Harbin Medical University, China. Dr Wan was born in Hong Kong and obtained his Bachelor of Science in Medical Technology from the National Taiwan University, Taiwan in 1984. He obtained his Master of Philosophy and Doctor of Philosophy degrees at the University of Hong Kong in 1992 and 1997 respectively. Dr Wan is one of the most experienced cancer cytogeneticist in Hong Kong.  He is certainly the best qualified as well as the most prolific. Dr Wan has been awarded the Membership of the Royal College of Pathologists of the UK (specialized in Clinical Cytogenetics) based on published works in 2003. This achievement is no small feat and is one that is bestowed to basic and clinical scientists whose work is considered of the highest calibre.  He was awarded the Fellowship of the Royal College of Pathologists in 2008.  Dr Wan has been attached to several laboratories in the USA and Canada for research training, including Harvard Medical School, University of British Columbia, and the California Institute of Biological Research.  He has been chosen by Cold Spring Harbor Laboratory (USA) to attend advanced molecular cytogenetics courses. He is now considered one of the regional experts on molecular cytogenetics procedures.  He has frequently been invited to deliver lectures at academic institutions and scientific conferences in Asia. Dr Wan is the scientific advisor and consultant in many institutions and the HKSAR government. Furthermore, he serves in the editorial board of the International Journal of Oncology, Journal of the Association of Genetic Technologists, Atlas of Genetics and Cytogenetics in Oncology and Haematology. To date, he has authored more than 120 reports, reviews and on-line publications in international peer reviewed journals.

Study of hematological malignancies and pediatric solid tumours, especially on the genesis of the chromosomal aberrations in tumorogenesis.

Yonghe Li joined Southern Research Institute as an Advanced Research Biochemist in 2005 after working as a Research Instructor at Washington University. He also currently serves as an adjunct Associate Professor of Pharmacology and Toxicology at The University of Alabama at Birmingham (UAB) and is a member of the UAB Comprehensive Cancer Center. Dr. Li received his B.S. in Pharmacology from Shanghai Medical University in China and his Ph.D. in Biochemistry from James Cook University in Australia. He completed his postdoctoral training in cell biology at Washington University School of Medicine in St. Louis.

Wnt Signaling in Cancer,  canonical Wnt signaling pathway is important in stem cell biology and embryonic development and can lead to tumor formation when aberrantly activated. Defining the roles of Wnt co-receptor LRP6 and its regulators in cancer tumorigenesis and metastasis.

Benjamin J Daniel is an Assistant Director- UTHSCSA Flow Cytometry Core – San Antonio,TX 2010 – Present Research Instructor -  UTHSCSA, Dept of Medicine – San Antonio, TX Direct and Manage the Flow Cytometry core facility. Manage Day to day operation of flow cytometry core. Train personnel on use of the instruments and data analysis. Manage core accounting to ensure we are within our operating budget. Consult with users about design and execution of experiments pertaining to flow cytometry. Responsible to strategically plan and implement core goals in regards to, finance, equipment, core personnel. Write annual progress reports. Seek and execute external funding opportunities for new core instruments. Keep core website updated with technologies and flow cytometry methods. Implement billing procedures to ensure that the core is properly paid for services rendered. Operate core machines (FACSAria and FACSCalibur) as needed.

Cancer Biology.

Yuki Hamano is an Assistant Professor of the Department of Nephrology, Chiba University Hospital, Chiba, Japan

Cancer Science.

Sivakumar Vallabhapurapu completed his graduate training at the University of Karlsruhe, Karlsruhe, Germany, and was a postdoctoral fellow at the Fritz Lipmann Institute for Age Research in Jena, Germany and at the University of California, San Diego. At UCSD he worked with Dr. Michael Karin studying the regulation of NF-kB transcription factors in the immune system. In 2009, Siva joined the University of Cincinnati in the Department of cancer and cell biology. Dr. Vallabhapurapu (Siva) laboratory studies the signaling pathways that regulate gene expression and control normal homeostasis and, when deregulated, lead to pathogenesis resulting in diseases such as cancer. For the past several years, Siva has been working towards understanding the regulation of NF-kB signaling, which plays a central role in immunity, inflammation, and cancer. Recently, he described a molecular mechanism by which one of the two arms of NF-kB signaling, the alternative signaling, is regulated.

Signaling pathways that regulate gene expression and control normal homeostasis and, when deregulated, lead to pathogenesis resulting in diseases such as cancer.

Janaina Fernandes is an Adjunct Professor of the Institute of Biophysics at Federal University of Rio de Janeiro. She has received a Ph.D in Biophysics from the Institute Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro. 2001-2005. Received the Carlos Chagas Filho Awards (2008). She is serving as reviewer for the Lung Journal (New York) and as reviewer for research grant application for the Brazilian Health System, Brazilian Health Ministery, and as Editorial board Member for the Journal of Bioequivalence & Bioavailability and Journal of Bioanalysis & Biomedicine. She is author and co-author of international patents and articles on medicinal chemistry, mostly in natural products research.